16 Sep Reunion Neuroscience Announces Final Closing of its Series A Financing and Plans to Advance RE104 into Clinical Development for the Treatment of Generalized Anxiety Disorder (GAD)

▤ Summary

Reunion Neuroscience closed its upsized Series A financing and raised a total of $133 million. The company will use the capital to support its ongoing Phase 2 programs and to expand RE104 into generalized anxiety disorder. Reunion expects to start the RECLAIM Phase 2 trial for GAD in the first quarter of 2026. The company also highlighted positive topline data from its RECONNECT study in postpartum depression and continued progress in adjustment disorder.

$ Funding

▦ Linked Companies